by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

Simtra BioPharma Solutions Warning Letter Details

Warning Letter

Simtra BioPharma Solutions

Building C, Suite 270, 2nd Floor 400 Interpace Parkway Parsippany , NJ 07054 United States

Issue DateMarch 03, 2026

FEI Number3002806419

Violations2

CountryUnited States

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

CGMP/Finished Pharmaceuticals/Adulterated

Simtra BioPharma Solutions FDA Warning Letter, March 3, 2026